Maria Cavallin

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

Bristi Basu, Emma Dean, M. Puglisi et al. · Clinical Cancer Research · 2015 · 128 citations

Medicine, Oncology, Pharmacology +14

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

Nigel Bundred, Jānis Gardovskis, Janusz Jaśkiewicz et al. · Investigational New Drugs · 2013 · 89 citations

Medicine, Pharmacokinetics, Pharmacology +12

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies

Roger B. Cohen, Steinar Aamdal, Marta Nyakas et al. · European Journal of Cancer · 2013 · 47 citations

Medicine, Oncology, Pharmacology +6

Best Practices in Performing Flow Cytometry in A Regulated Environment: Feedback from Experience Within The European Bioanalysis Forum

Barry van der Strate, Robin Longdin, Marie Geerlings et al. · Bioanalysis · 2017 · 45 citations

Pharmacy, Cell Biology, Biopharmaceutics +6